AO 128

Known as: AO-128, epi-Inositol, 2,3-dideoxy-2-((2-hydroxy-1-(hydroxymethyl)ethyl)amino)-4-C-(hydroxymethyl)- 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1989-2009
02419892009

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1998
1998
BACKGROUND The most widely used treatment of portal-systemic encephalopathy (PSE) is the administration of oral, non-absorbable… (More)
Is this relevant?
1997
1997
Objective: Voglibose is a new and potent inhibitor of α-glucosidases and is used for the treatment of diabetes mellitus. Since… (More)
  • figure 1
  • figure 2
  • table 1
Is this relevant?
1997
1997
To know whether the insulin resistance is improved by delaying carbohydrate absorption from the small intestine, we studied the… (More)
Is this relevant?
1997
1997
Objective: Voglibose is a new and potent inhibitor of α-glucosidases used for treatment of diabetes mellitus. It increases gastro… (More)
  • figure 1
  • table 1
  • figure 2
Is this relevant?
1995
1995
The alpha-glucosidase inhibitor voglibose (AO-128) was designed to prevent rapid postprandial blood glucose rises in non-insulin… (More)
Is this relevant?
1995
1995
The present study was designed to determine the possible significance of a therapeutic dose (0.2 mg) of AO-128 on carbohydrate… (More)
Is this relevant?
1995
1995
Antiobesity and antidiabetic actions of the alpha-glucosidase inhibitor AO-128 were examined using genetically obese-diabetic… (More)
Is this relevant?
1992
1992
A new disaccharidase inhibitor, AO-128, showed 190-3900-fold more potent inhibition of purified rat small intestine sucrase… (More)
Is this relevant?
1992
1992
To investigate the mechanism of oral carbohydrate-stimulated secretion of the two most potent incretin candidates, gastric… (More)
Is this relevant?
1989
1989
The relationship between mesenteric fat accumulation and metabolic disorder was studied in genetically obese Zucker fatty rats… (More)
Is this relevant?